TY  - JOUR
AU  - Hermosilla, Jesus
AU  - Perez-Robles, Raquel
AU  - Salmeron-Garcia, Antonio
AU  - Casares, Salvador
AU  - Cabeza, Jose
AU  - Navas, Natalia
AU  - https://www.sciencedirect.com/science/article/pii/S0731708521003204?via%3Dihub
PY  - 2021
DO  - 10.1016/j.jpba.2021.114209
UR  - http://hdl.handle.net/10668/18028
T2  - Journal of pharmaceutical and biomedical analysis
AB  - A range of biopharmaceutical products are used to target Vascular Endothelial Growth Factor (VEGF), including Eylea® (aflibercept, AFL) and Zaltrap® (ziv-aflibercept, ziv-AFL). The first is indicated for ophthalmological diseases such as neovascular...
LA  - en
PB  - Science Direct
KW  - Fc-fusion protein
KW  - Infusion bags
KW  - Stability study
KW  - Ziv-Aflibercept
KW  - Infusions, Parenteral
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - Recombinant Fusion Proteins
KW  - Vascular Endothelial Growth Factor A
TI  - Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies.
TY  - research article
VL  - 203
ER  -